- Hits: 201
Nanomol Technologies has obtained an AGAUR grant in the 2020 call to participate in an Industrial Doctorate project in collaboration with the ICMAB. The project, entitled “Synthesis of new vesicular systems for the integration of biomolecules” will allow a PhD candidate to carry out the PhD Thesis project between both entities during 3 years.
On 11-19 November 2020, a virtual immersion in the Silicon Valley health and entrepreneurship ecosystem (DISRUPTOUR) will take place in digital format. The initiative, organized by Biocat and ACCIÓ (Silicon Valley office), will allow companies and projects to meet and interact with top investors, companies, and academic agents in the health sector in the United States. Register before 11 September 2020!
The International Meeting for Chemistry Expoquimia hosted the UNPRECEDENTED Industrial Dialogues Webinars, seminars discussing different topics related to the cores of the triennial meeting: circular economy, digitalization, and technology transference. This last topic was covered in one webinar by Nora Ventosa, from the Molecular Nanoscience and Organic Materials (NANOMOL) group.
The ICMAB is now a member of SECPHO, a national technological innovation cluster formed by companies, technology centres and research centres. SECPHO is focused on promoting technological unnovation through the application of photonic technologies, or technologies based on light, to all types of sectors of our economy.
In 2019 the ICMAB applied for 4 priority patent applications, all of them European, and for an extension in Europe of a French priority patent. This means that from the 34 European patent applications from the CSIC, 5 are from the ICMAB (nearly 15 %). The CSIC leads the European patents applied in Spain, and there is a new record of European patent applications from Spanish origin according to the 2019 Patent Index of the European Patent Office (EPO).
Biocat has opened the call for applications to the second edition of CRAASH Barcelona, a 12-week acceleration program that helps research teams from Catalonia and other European countries successfully launch innovation to market in the healthtech arena. The deadline for applications is 16 March.
Magnetic resonance imaging (MRI) is a commonly used clinical imaging technique for noninvasive diagnosis and characterization of soft tissues. The technique provides images in excellent detail of tumors and related pathological conditions thanks to the contrast agents used in the procedure. Now, a group of researchers from the ICMAB led by José Vidal-Gancedo, from the Nanomol Group, have developed organic metal-free magnetic resonance imaging (MRI) contrast agents based on dendrimers with a totally innovative synthesis procedure.
A technology developed by a team led by Dr. Núria Crivillers, researcher at the Nanomol Group at ICMAB, has been selected as a high potential innovation by the European Union (EU).